AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

EU, Japan and other countries for the treatment of certain paediatric patients with NF1 who have symptomatic, inoperable PN. In July 2017, AstraZeneca and Merck & Co., Inc., Rahway, NJ, US, known as ...

Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...

United Nations Secretary-General Antonio Guterres told world leaders at the COP29 summit on Tuesday to "pay up" to prevent ...

EU mid-market update: Trump trade train in full steam ahead mode; Germany dials in election for Feb 23rd, while its ZEW index ...

German business confidence has collapsed, industry data show, as Olaf Scholz announced Germany will hold national elections ...

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding ...

Bayer said on Tuesday that weak agricultural markets mean its earnings are likely to fall further next year, sparking a sharp ...

AstraZeneca (AZ) has begun the second quarter ... leading to cell death. EU breast cancer use for Lynparza? In a separate development AZ and partner Merck & Co, known as MSD outside the US ...

On October 31, 2024, the European Commission (EC) fined Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva) ...